Compare Amgen, Inc. (AMGN) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Berkshire Hathaway Inc Class B — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Berkshire Hathaway Inc Class B trades at $498.98. The key difference: Amgen, Inc. pays a 2.77% dividend while Berkshire Hathaway Inc Class B pays none. Which is the better fit depends on your goals.
| AMGN | BRK.B | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Financials |
52-Week High | $388.16 | $513.70 |
52-Week Low | $271.18 | $459.10 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BRK.B trades at $495.49, up 0.37% on the day, with mixed technical signals showing a bearish overall trend but bullish moving averages. Analyst consensus is positive with 57% buy ratings, though key financial ratios are unavailable in the current dataset. The stock faces resistance near $497 and support at $492.
The outlook remains cautiously optimistic given strong analyst support, but the lack of recent fundamental data and bearish technical indicators suggest near-term volatility. Key risks include market sensitivity and execution challenges in Berkshire Hathaway's diverse holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
